Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

Ten years after first collecting an FDA approval, it’s time for version number two. | Cologuard Plus represents the next ...

A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care ...

Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, ...

Mosnodenvir is designed to block interactions between two dengue virus proteins. The vaccine survived J&J’s decision last ...

One of those companies, a contract research organization focused on genetic medicines called Franklin Biolabs, officially ...

Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a ...

As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with ...

Kurma plans to raise a total of 250 million euros ($276 million) for the fund, dubbed Biofund IV, which would make it the ...

The digital pathology developer Proscia is launching an artificial intelligence toolkit for life science researchers, ...

Legend Biotech appears to be on a mission to shake up its cell therapy development. | A week after signing up to collaborate ...